Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

ELAFIBRANOR
(D11208)

[1] Elafibranor

[1] Elafibranor (D11208) 💬

[1] PPARA 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[2] 93, 94 💬

2

Elafibranor 120 mg
(D11208)

[1] Elafibranor

[1] Elafibranor (D11208) 💬

[1] PPARA 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[2] 93, 94 💬

3

Elafibranor 80 mg
(D11208)

[1] Elafibranor

[1] Elafibranor (D11208) 💬

[1] PPARA 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[2] 93, 94 💬

4

Elafibranor 80mg
(D11208)

[1] Elafibranor

[1] Elafibranor (D11208) 💬

[1] PPARA 💬

[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬

[1] 93 💬